Detail page

Knowledge Web

Person

Christoffer Gebhardt (1976-)

Arzt

Name	Christoffer Gebhardt
Time	1976- (Date of birth and death)
Place	Marburg (Geburtsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession)
Further information	Diss. Medizinische Fakultät; bis 09/2017 Funktionsoberarzt an der Klinik für Dermatologie, Venerologie und Allergologie der Medizinischen Fakultät Mannheim der Universität Heidelberg und dortiger Arbeitsgruppenleiter der Dermatoonkologische Kooperationseinheit; seit 11/2017 Oberarzt, Leiter des Hauttumorzentrums und Leiter der Experimentellen Dermatologie an der Klinik und Poliklinik für Dermatologie und Venerologie des Universitätsklinikums Hamburg-Eppendorf
Record type	Person
GND-Identifier	13051151X
Record ID	13051151X
Involved in show all Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition Von der Adjuvans zur Neoadjuvans: Neue Therapieansätze in der Systemtherapie des Melanoms Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: a multicenter study from the prospective skin cancer registry ADOREG Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – a multicenter study on 2419 patients from the prospective skin cancer registry ADOReg Outcome of systemic therapy in patients with advanced rare skin cancers: a retrospective multicenter DeCOG study of 209 patients Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : a multicenter study from the prospective skin cancer registry ADOREG Fakten kompakt: Opdivo® Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium IIB/C und III und IV Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - a multicenter study on 2,419 patients from the prospective skin cancer registry ADOReg Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: a multicenter study on 1383 patients of the prospective DeCOG registry ADOReg Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg Langfristiges Management des fortgeschrittenen Basalzellkarzinoms: Aktuelle Herausforderungen und Zukunftsperspektiven Analyse der Funktion Eosinophiler Granulozyten bei der Progression und der Systemtherapie des malignen Melanoms Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG Cemiplimab (Libtayo®) beim fortgeschrittenen Basalzellkarzinom : Erfahrungen aus der Praxis nach HHI-Therapie Die Rolle von S100A8/A9 und neutrophilen Granulozyten im Serum sowie deren Wirkung in der Tumor-Mikroumgebung beim malignen Melanom Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG Langfristiges Management des fortgeschrittenen Basalzellkarzinoms : Aktuelle Herausforderungen und Zukunftsperspektiven Status quo and future perspectives of molecular diagnostics in dermatology Status quo und Zukunftsperspektiven der molekularen Diagnostik in der Dermatologie Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care: A Randomized Pilot Study Die Schildwächterlymphknoten-Biopsie beim Malignen Melanom der Haut: Prognostisch wichtig oder ersetzbar? Fakten kompakt Opdivo Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma : A Series of 12 Patients Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry CD74 and CD44 expression on CTCs in cancer patients with brain metastasis Cemiplimab (Libtayo) : die erste zugelassene Therapie beim metastasierten oder lokal fortgeschrittenen kutanen Plattenepithelkarzinom Factors Influencing the Adjuvant Therapy Decision : Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients Fakten kompakt Opdivo Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV Surveillance of patients with conjunctival melanoma in German-speaking countries: a multinational survey of the German dermatologic cooperative oncology group [Letter] Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Epidemiologie von Hautkrankheiten in Deutschland : systematische Literaturanalyse des aktuellen Forschungsstandes Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis Fakten kompakt Opdivo Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma Myeloid-derived suppressor cells and tumor escape from immune surveillance Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation Identifizierung und Analyse Tumor-assoziierter c-Fos-, AP-1-Zielgene in der Karzinogenese der Maushaut

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Christoffer Gebhardt (1976-)

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition

Von der Adjuvans zur Neoadjuvans: Neue Therapieansätze in der Systemtherapie des Melanoms

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: a multicenter study from the prospective skin cancer registry ADOREG

Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – a multicenter study on 2419 patients from the prospective skin cancer registry ADOReg

Outcome of systemic therapy in patients with advanced rare skin cancers: a retrospective multicenter DeCOG study of 209 patients

Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : a multicenter study from the prospective skin cancer registry ADOREG

Fakten kompakt: Opdivo® Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium IIB/C und III und IV

Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - a multicenter study on 2,419 patients from the prospective skin cancer registry ADOReg

Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: a multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Langfristiges Management des fortgeschrittenen Basalzellkarzinoms: Aktuelle Herausforderungen und Zukunftsperspektiven

Analyse der Funktion Eosinophiler Granulozyten bei der Progression und der Systemtherapie des malignen Melanoms

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Cemiplimab (Libtayo®) beim fortgeschrittenen Basalzellkarzinom : Erfahrungen aus der Praxis nach HHI-Therapie

Die Rolle von S100A8/A9 und neutrophilen Granulozyten im Serum sowie deren Wirkung in der Tumor-Mikroumgebung beim malignen Melanom

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG

Langfristiges Management des fortgeschrittenen Basalzellkarzinoms : Aktuelle Herausforderungen und Zukunftsperspektiven

Status quo and future perspectives of molecular diagnostics in dermatology

Status quo und Zukunftsperspektiven der molekularen Diagnostik in der Dermatologie

Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care: A Randomized Pilot Study

Die Schildwächterlymphknoten-Biopsie beim Malignen Melanom der Haut: Prognostisch wichtig oder ersetzbar?

Fakten kompakt Opdivo Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives

Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma : A Series of 12 Patients

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry

CD74 and CD44 expression on CTCs in cancer patients with brain metastasis

Cemiplimab (Libtayo) : die erste zugelassene Therapie beim metastasierten oder lokal fortgeschrittenen kutanen Plattenepithelkarzinom

Factors Influencing the Adjuvant Therapy Decision : Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Fakten kompakt Opdivo Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV

Surveillance of patients with conjunctival melanoma in German-speaking countries: a multinational survey of the German dermatologic cooperative oncology group [Letter]

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Epidemiologie von Hautkrankheiten in Deutschland : systematische Literaturanalyse des aktuellen Forschungsstandes

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Fakten kompakt Opdivo Adjuvant : zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV

CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma

Myeloid-derived suppressor cells and tumor escape from immune surveillance

Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation

Identifizierung und Analyse Tumor-assoziierter c-Fos-, AP-1-Zielgene in der Karzinogenese der Maushaut